# Diabetes Research Hub — Monitor Report
**Run date:** 2026-08-12 (automated review run)
**Reviewer:** Hub monitor (read-only; no source files modified)

---

## TL;DR — What's Actionable

**This is the sixth consecutive report flagging the same collector outage, now day 26. The decision in front of a human is no longer "restart the collectors" — it's "either restart them today, or pause this daily monitor." Running an unchanged stale-data warning every morning is now costing attention without adding signal.** Every "latest" data file is still frozen at **2026-07-17** (`clinical_trials_latest.json` metadata: `generated 2026-07-17T02:05:53`; `pubmed_recent_latest.json`: `2026-07-17T02:06:39`; newest snapshot of either type is dated 2026-07-17). No collector output has been written in 26 days. [Certain]

**Two net-new items this cycle that are worth a human's eyes:**

1. **A retraction, not a finding.** Yesterday's report (08-11) carried a **[Likely]** claim that Vertex had "temporarily postponed completion of dosing in the zimislecel (VX-880) program pending an internal manufacturing analysis." I could not confirm that against any primary source today. Vertex's only "Program Updates for Type 1 Diabetes Portfolio" release is dated **March 28, 2025** and says the opposite — zimislecel Phase 3 on track, VX-264 (the "cells + device" program) is the one that was discontinued for lack of efficacy. Vertex's **June 2026 ADA** presentation reported positive zimislecel data (10–12 dosed patients insulin-independent at 1 year). **Downgrade the postponement claim to [Guessing] and treat it as unverified.** It looks like a conflation of the discontinued VX-264 program with zimislecel. Do not carry it forward as fact.

2. **A real Phase 3 readout the frozen corpus can't see.** Eli Lilly's **retatrutide** (triple GIP/GLP-1/glucagon agonist — a tracked therapy) reported positive **TRIUMPH-2 and TRIUMPH-3** Phase 3 results in **late July 2026** (≈20.8% and 22.6% weight loss at 80 weeks; the T2D program showed HbA1c reductions of ~1.7–1.9% vs 0.8% placebo). BLA now expected **Q1 2027**. This post-dates the 07-17 freeze and is not in the corpus. [Likely — multiple secondary outlets; confirm against Lilly IR before citing in the tracker.]

**Everything else below is reference state carried forward from the 2026-07-17 freeze. It has not changed and is not current intelligence.**

---

## File System Status

| File | Last modified | Age | Status |
|------|--------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 26 d | ⚠️ STALE (>14 d) |
| `pubmed_recent_latest.json` | 2026-07-17 | 26 d | ⚠️ STALE (>14 d) |
| `hub_monitor_report.md` | 2026-07-17 | 26 d | ⚠️ STALE (>14 d) |
| `literature_gap_data.json` | 2026-07-18 | 25 d | ⚠️ STALE (>14 d) |
| `literature_gap_report.md` | 2026-08-11 | 1 d | Fresh mtime — but re-runs on the frozen corpus (header: "Date range: 2020/01/01 to 2026/07/17") |
| `agent_state.json` | 2026-08-11 | 1 d | Current (backup rotation still running) |

**Same split as the last five days: two schedulers, one broken.** The analysis/iterate pipeline is alive — `literature_gap_report.md` (2026-08-11), `citation_validation.json`/`evidence_network.json`/`gap_evidence.json` (2026-08-10), and the `agent_state.json` daily backup rotation all carry recent mtimes. The three *collectors* (`baseline_clinical_trials.py`, `baseline_pubmed_alerts.py`, `hub_monitor.py`) have written nothing since 2026-07-17. A fresh mtime on the gap report is not fresh data — it re-analyzes the cached 2026-07-17 PubMed pull and reproduces identical rankings. [Certain]

---

## Clinical Trial Changes

**No snapshot since 2026-07-17 → nothing to diff.** Numbers below are the frozen 2026-07-17 state (858 trials), reference only.

Category counts (frozen): T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 76 · T2D Novel Therapies 147 · Diabetes Technology 236 · Recently Completed w/ Results 321.
Status mix (frozen): 321 COMPLETED · 269 RECRUITING · 151 NOT_YET_RECRUITING · 110 ACTIVE_NOT_RECRUITING · 7 ENROLLING_BY_INVITATION. 52 trials Phase 3 + RECRUITING.

Key Phase 3 trials from tracked sponsors (status frozen at 2026-07-17 — verify live before citing): NCT06832410 & NCT04786262 (Vertex, zimislecel, RECRUITING) · NCT07222332 & NCT07222137 (Lilly, baricitinib, RECRUITING) · NCT07564414 (Novo, CagriSema, RECRUITING) · NCT07076199 (Novo, insulin icodec, RECRUITING) · NCT06739122 (Lilly, dulaglutide pediatric, RECRUITING).

**Note on the two Vertex NCTs:** last cycle flagged them for status re-check on the assumption zimislecel dosing was postponed. Per the retraction above, that assumption is unverified — the primary record has zimislecel progressing, not paused. Still worth a live re-check once collectors restart, but not because of a confirmed postponement.

---

## PubMed Highlights

**Frozen at 2026-07-17** (158 unique papers, 16 domains, 30-day lookback). No new papers in 26 days. Highest-value cross-domain papers from the frozen set (carried, unchanged):

- **[42459945]** *Algorithmic discrimination risks in training data — pediatric T1D* — Diabetes AI/ML × Closed Loop AP × Health Equity (only triple-domain paper).
- **[42419792]** *Comparative effects of obesity drugs (systematic review)* — orforglipron × retatrutide × CagriSema in one head-to-head.
- **[42458730]** / **[42459212]** — Multi-omic BMI response / precision-nutrition multi-omics (Microbiome × Multi-Omics).

Key-therapy mentions (frozen 30-day window): dapagliflozin 52 · orforglipron 10 · CagriSema 6 · retatrutide 4 · teplizumab 4 · icodec 3 · baricitinib 2 · **zimislecel 0**. The live literature has moved (see retatrutide TRIUMPH-2/-3 above) but the corpus cannot reflect it until the PubMed collector runs.

---

## Gap Analysis Summary

Top intersections from `literature_gap_report.md` (regenerated 2026-08-11 on the frozen corpus — **validation level BRONZE**, single analytical source, expert confirmation required):

1. Treg / CAR-T × Neuropathy — 100.0 (0 joint pubs)
2. Beta Cell Regen × Health Equity — 100.0 (0)
3. Treg / CAR-T × Health Equity — 100.0 (0)
4. Glucokinase × Health Equity — 100.0 (0)
5. Gene Therapy × LADA — 100.0 (0)

**Alignment with Tier 1 doctrine areas:** Health Equity (Doctrine Tier 1 #6, Epidemiological/Disparity Analysis) appears in four of the top seven gaps (#2, #3, #4, and Drug Repurposing × Health Equity at #6). Drug Repurposing is Tier 1 #4, so **Drug Repurposing × Health Equity (#6, gap 100.0, 0 joint pubs) is a double-Tier-1 intersection** and remains the strongest candidate for a computational contribution. Multi-Omics (Tier 1 #1) surfaces lower down via Metabolomics × Health Equity (87.1). Doctrine caveat still applies: 100.0 scores with 0 joint pubs are as likely to be terminology artifacts as real gaps — each needs a manual combined-term PubMed search before it earns Silver, and that search should run against a *refreshed* corpus.

---

## Breaking News (web check, last ~7 days)

- **Retatrutide TRIUMPH-2 / TRIUMPH-3 positive Phase 3 (late July 2026); BLA expected Q1 2027.** Genuinely significant, maps to tracked therapy. [Likely — secondary coverage; confirm against Lilly IR.] Not in the frozen corpus.
- **Zimislecel "manufacturing postponement" — NOT confirmed.** Carried from yesterday as [Likely]; primary Vertex source (Mar 2025 program update) and June 2026 ADA data contradict it. Downgraded to [Guessing]; treat as retracted pending a real primary source.
- **No new FDA diabetes approval in the last 7 days.** Orforglipron (Foundayo, Lilly) was approved for weight management **April 1, 2026**; its T2D indication filing is tracked and still pending — no August action found. Routine.

---

## Recommended Actions

1. **[Decision, day 26] Pick one today: restart the collectors, or pause this monitor.** Six identical reports have not moved the outage. If the collectors matter, run them manually now and capture the failure mode: `python baseline_clinical_trials.py && python baseline_pubmed_alerts.py && python hub_monitor.py`. Clean run + no new snapshot → scheduler/cron is disabled (ops problem). Traceback → API/auth/endpoint break at the 2026-07-17 boundary. If they don't matter right now, switch this task to weekly so the daily noise stops.
2. **Retract the zimislecel postponement claim** from the running narrative unless a dated primary Vertex/IR source is found. Do not re-flag NCT06832410 / NCT04786262 as "likely status-changed due to postponement" — that inference rested on the unverified claim.
3. **Log the retatrutide TRIUMPH-2/-3 readout** as a manual tracker entry (evidence: [Likely], secondary sources) so it isn't lost while the PubMed collector is down. Confirm against Lilly IR before promoting to [Certain].
4. **Do not act on gap rankings yet.** BRONZE, computed on a 26-day-old corpus. Re-run `project1_literature_gap_analysis.py` *after* the collectors restart.

---

*Automated review run — read-only. No source files were modified. Web claims labeled [Likely]/[Guessing] require primary-source confirmation. Gap classifications are BRONZE pending expert validation per Research Doctrine v1.0.*
